Stem Cell Clinic

High Rate of Responses Seen With Ide-cel in Heavily Pretreated Myeloma – Targeted Oncology

By adminMay 30, 2020Stem Cell Medicine

Treatment with idecabtagene vicleucel (ide-cel; bb2121) led to responses in 73% of heavily pretreated patients with relapsed or refractory multiple myeloma, and complete responses (CRs) in 33%, according to topline findings from the pivotal phase 2 KarMMA trial.

Data shared during the 2020 ASCO Virtual Scientific Program demonstrated a median duration of response (DOR) of 10.7 months, and amedian progression-free survival (PFS) of 8.8 months (95% CI, 5.6-11.6).

Ide-cel demonstrated frequent, deep, and durable responses in heavily pretreated, highly relapsed/refractory patients with myeloma, said Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and professor of Medicine, Harvard Medical School. Overall, ide-cel provides an attractive option for the treatment of patients with triple-class exposed relapsed/refractory myeloma.

In March 2020, Bristol Myers Squibb andbluebird bio, Inc., the codevelopers of ide-cel, submitted a Biologics License Application (BLA) to the FDA for the use of the BCMA-targeting chimeric antigen receptor (CAR) T-cell therapy as a treatment for adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

However, earlier this month, the FDA issued aRefusal to File letter tothe companies regarding the BLA. In its initial review, the agency concluded that additional information was needed for the Chemistry, Manufacturing and Control module of the BLA. The FDA did not ask for any further clinical or nonclinical data according to the companies, which plan to resubmit the application by the end of July of this year.

The phase 2 KarMMA trial (NCT03361748) included 128 patients with relapsed/refractory multiple myeloma who received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

The median age was 61 months (range 33-78), 35% of patients had high-risk cytogenetics, 51% had high tumor burden, 39% had extramedullary disease, and 85% had 50% tumor BCMA expression. ECOG performance status was 0 (45%), 1 (53%), or 2 (2%). R-ISS disease stage was I (11%), 2 (70%), or III (16%). Patients had received a median of 6 (range, 3-16) prior antimyeloma regimens.

Ninety-four percent of patients had received 1 prior autologous stem cell transplant, and 34% had received more than 1. Eighty-eight percent of patients received bridging therapies during CAR T-cell manufacturing; however, only 4% of patients responded to the treatment. Regarding refractory status, 94% of patients were refractory to anti-CD38 antibodies and 84% were triple refractory.

Patients were treated at CAR+ T cell doses of 150 x 106 (n = 4), 300 x 106 (n = 70), or 450 x 106 (n = 54). The median follow-up was 18 months, 15.8 months, and 12.4 months, respectively. Across all patients, the median follow-up was 13.3 months. The primary end point was objective response rate (ORR), with secondary end points including CR, DOR, PFS, overall survival (OS), and quality of life.

Across all patients, the 73% ORR (95% CI, 65.8%-81.1%; P <.0001) included a 33% CR rate (95% CI, 24.7-40.9; P <.0001), a 20% very good partial response rate, and a 21% partial response rate. The overall CR rate comprised 26% of patients who achieved a CR/stringent CR (sCR) and were minimal residual disease (MRD)-negative, and 7% of patients who achieved a CR/sCR but who did not have MRD data. The median time to first response was 1 month (range, 0.5-8.8) and the median time to CR was 2.8 months (range, 1-11.8).

Durable responses were observed across all doses, said Munshi. At the dose of 450 x 106 CAR+ T cells, the ORR was 82% and the CR/sCR rate was 39%.

Clinically meaningful efficacy in terms of ORR was observed across subgroups, irrespective of age, risk categorization, tumor burden, BCMA expression level, extramedullary disease, triple-refractory status, penta-refractory status, and bridging therapy.

PFS increased as the target dose increased. At the 450 x 106 CAR+ T-cell dose, the median PFS was 12.1 months (95% CI, 8.8-12.3). The median PFS also increased by depth of response with a median of 20.2 months (95% CI, 12.3not evaluable) among patients who achieved a CR/sCR.

Munshi said the survival data are immature. At the time of the analysis, the median OS was 19.4 months (95% CI, 18.2not evaluable) and the 1-year OS rate was 78%.

Cytokine release syndrome (CRS) frequency increased with dose but was mostly low-grade, said Munshi. Overall, 84% of patients had 1 CRS event, with the majority (78%) being grade 1/2. There were 5 cases of grade 3 CRS, 1 case of grade 4, and 1 case of grade 5. The median time to onset of CRS was 1 day (range, 1-12), and the median duration of CRS was 5 days (range, 1-63). Fifty-two percent of patients received tocilizumab (Actemra) for CRS management, and 15% of patients received corticosteroids.

Neurotoxicity was mostly low grade and was similar across target doses, said Munshi. Overall, 18% of patients had 1 neurotoxicity event. There were 19 cases of grade 1/2 neurotoxicity and 4 cases of grade 3. There were no grade 4 or 5 incidents. The median time to onset of neurotoxicity was 2 days (range, 1-10), and the median duration was 3 days (range, 1-26). Two percent of patients received tocilizumab for neurotoxicity, and 8% of patients received corticosteroids.

The other significant adverse event, according to Munshi, was cytopenia91% of patients had any grade neutropenia (89% grade 3), and 63% (52% grade 3) had any grade thrombocytopenia. The median time to recovery of grade 3 neutropenia and thrombocytopenia was 2 months and 3 months, respectively, said Munshi.

There were 5 deaths within 8 weeks of ide-cel infusion2 following myeloma progression and 3 from AEs (CRS, aspergillus pneumonia, and GI hemorrhage). There was also 1 other AE-related death (CMV pneumonia) that occurred within 6 months, in the absence of myeloma progression.

Reference

Munshi NC, Anderson Jr LD, Jagannath S, et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. Presented at: 2020 ASCO Virtual Scientific Program; May 29-31, 2020. Abstract 8503.

Continue reading here:
High Rate of Responses Seen With Ide-cel in Heavily Pretreated Myeloma - Targeted Oncology

Study reveals factors influencing outcomes in kidney cancer treated with immunotherapy – Science Codex

By adminMay 30, 2020Stem Cell Medicine

BOSTON - By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

The research was presented during the Clinical Science Symposium at the American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in Nature Medicine. The researchers say the study provides important clues about kidney cancer genetics and its interaction with the immune system that may prove to be vital in our ability to predict which patients are likely to benefit from immunotherapy drugs, which have been approved for first- and second-line treatment in the disease, but which don't work in all patients. The study showed that features that are typically linked to immunotherapy response or resistance in other types of cancer don't work the same way in advanced clear cell renal cell cancer (ccRCC).

"Kidney cancer breaks all those rules," said David Braun, MD, PhD, a Dana-Farber kidney cancer specialist and first author of the report. Co-senior authors are Toni Choueiri, MD, Catherine J. Wu, MD, Sachet A. Shukla, PhD, and Sabina Signoretti, MD all of Dana-Farber. Other authors are from the Broad Institute of MIT and Harvard, Bristol Myers Squibb, and Brigham and Women's Hospital.

Clear cell renal cell cancer is the most common form of kidney cancer. There are about 74,000 new cases of kidney cancer in the United States each year, and about 15,000 deaths. Checkpoint inhibitor immunotherapy drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo) used in advanced kidney cancer work by blocking PD-1, a protein on immune T cells that normally keep these cells from attacking other cells in the body. By blocking PD-1, these drugs boost the immune response against kidney cancer cells.

PD-1 checkpoint inhibitors have brought a powerful new weapon to bear on advanced kidney cancer, which generally doesn't respond to standard chemotherapy. In cancers such as melanoma and lung cancer, checkpoint inhibitors - drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) - tend to be more effective against tumors with a "high mutational burden," that is, their DNA is riddled with many mutations. Advanced clear cell renal cell cancer, by contrast, has a moderate number of mutations yet is relatively responsive to checkpoint inhibitors - and scientists don't know why that is. Another puzzling difference is that in melanoma and some other cancers, tumors that are infiltrated with large numbers of immune CD8 T cells, creating what's termed an inflamed or "hot" environment within the tumor, respond better to PD-1 blockade. But the reverse is true in advanced kidney cancer - high infiltration by CD8 T cells is associated with a worse outcome.

In this study, the scientists analyzed 592 tumors collected from patients with advanced kidney cancer who were enrolled in clinical trials of PD-1 blocking drugs. They used whole-exome and RNA sequencing and other methods to uncover the genomic changes and other factors that were associated with how the patients' tumors responded to the drugs - specifically, the patients' progression-free survival and overall survival.

The study was aimed at determining what features of advanced kidney cancer cells were associated with their response or resistance to PD-1 inhibitors. In analyzing the tumors from advanced ccRCC patients treated with PD-1 inhibitors, the investigators looked for biomarkers - genetic changes, mutations, copy number alterations, and so forth - in the genomes of the kidney cancer cells that might be correlated with patient outcomes - such as progression-free survival and overall survival.

Braun said that some of the most interesting findings were characteristics of the kidney tumors that - unlike with other types of cancer - did not influence responsiveness to PD-1 inhibitor drugs. For example, tumors containing a large number of neoantigens - proteins made by cancer-related DNA mutations that may make the tumors more responsive to immunotherapy, but this proved not to be true of the kidney tumors. Also, even though the kidney tumors were heavily infiltrated by CD8 immune T cells - which causes other kinds of cancer to provoke a strong immune attack against the tumors - this actually led to no difference in outcome for these kidney cancer patients. "To our surprise, the immunologically 'hot' tumors did not respond any better than the 'cold' tumors," said Braun.

Another factor that affects responsiveness in some types of cancer - the specific HLA molecules inherited by individuals that present antigens to the immune system - didn't affect the immune response to advanced kidney tumors. "That surprised us," said Dr. Wu, chief of Division of Stem Cell Transplantation and Cellular Therapies. "We reasonably hypothesized that the potential of the patient's immune system to present and react to a greater diversity of antigens may be associated with better outcomes, but clearly kidney cancer does not fit the standard mold," noted Wu.

"However, we did uncover some factors that may explain the unexpected observations," said Dr. Shukla who leads the computational group at the Dana-Farber Translational Immunogenomics Laboratory. The study uncovered that advanced kidney tumors heavily infiltrated with CD8 T cells did not respond well to immune checkpoint blockers even though they were immunologically "hot" tumors. The scientists, with their comprehensive analysis of changes in the kidney tumors' genomes, found that the tumors were depleted of mutated PBRM1 genes - which are correlated with improved survival with PD-1 blockade therapy - and also had an abundance of deletions of a chromosomal segment known as 9p21.3, which is associated with worse outcomes with PD-1 blockade. "We believe that these two factors may explain why CD8 T cell infiltration of the tumors did not make them responsive to checkpoint blocker therapy," explained Shukla, "while other types of cancer that exhibited CD8 T cell infiltration but did not have those chromosomal changes did respond."

"Our work highlights the importance of integrating genomic data with immunopathologic data generated through painstaking review by expert pathologists," said Dr. Signoretti, professor of pathology at Harvard Medical School. "Our findings reveal that interactions between immune T cell infiltration and alterations in the tumor DNA (such as inactivation of the PBRM1 gene and the abundance of 9p21.3 deletions) can be important influences on tumors' response to PD-1 blockade - perhaps not only in kidney cancer but in other types of tumors as well."

"The current study provides critical insights into immunogenomic mechanisms contributing to response and resistance to immunotherapy in clear cell renal cell cancer," said Dr. Choueiri, director of the Lank Center for Genitourinary Oncology and the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. "The detailed clinical, genomic, transcriptomic, and immunopathology data produced by this study will serve as a valuable resource for the cancer immunology community. This work, therefore, will be important for ongoing research in precision medicine and immuno-oncology, helping to identify which patients are likely to respond to current therapies, and providing fundamental information to aid in development of rational combination therapies to overcome resistance in the future."

"One notable thing," said Choueiri, "is the collaboration between multiple disciplines and stakeholders: Immunology, pathology, genetics, computational and clinical expertise all converged on one tumor, while involving academic and industry stakeholders."

See the rest here:
Study reveals factors influencing outcomes in kidney cancer treated with immunotherapy - Science Codex

Global, The US and Europe Regenerative Medicines Market Outlook 2019-2027 Share, Consequence of COVID-19 on Market, Demand, Top Companies, Trend,…

By adminMay 30, 2020Stem Cell Medicine

The global regenerative medicine market is estimated to grow on the back of rising healthcare expenditure with increasing demand for efficient disease treating practices coupled with growing technological developments and discoveries. The world bank reported a rise in global current health expenditure (% GDP) from 9.453% in 2011 to 10.023% in 2016.

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

Request to Fill the Form to Get Sample Copy of This Report:https://www.kennethresearch.com/sample-request-10166486

Additionally, global regenerative medicines market is estimated to grow at a robust rate on the back of increasing adoption of stem cell technology to address the rising prevalence of chronic diseases. Moreover, emerging applications of gene therapy in regenerative medicines for tackling infectious diseases such as, malaria, HIV, tuberculosis and influenza or to target angiogenesis during cardiac surgery is leading to subsequent expansion in usage base of regenerative medicines around the globe.

Increasing incidences of chronic oncogenic diseases such as cancer with an estimated new cases of 18.1 million in 2018 as per International Agency for Research on Cancer (IARC), is anticipated to display rapid growth in application of regenerative medicines in the upcoming years. Additionally, increasing application of regenerative medicines to treat auto-immune hepatitis, is expected to back the rampant growth in the upcoming years. Moreover, government initiatives to eliminate chronic diseases is anticipated to aid the growth in upcoming years.

For instance, World Health Organization (WHO) launched an initiative to eliminate hepatitis completely by 2030. Furthermore, Regenerative medicines comprising blood stem cell implants can be used to restore healthy bone marrow in patients with leukemia. Besides, experiments in the gene therapy segment to explore benefits for various other medical applications, is expected to propel considerable growth in the regenerative medicines market in the upcoming years.

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

Request to Fill the Form to Get Sample Copy of This Report:https://www.kennethresearch.com/sample-request-10166486

Application of regenerative medicines in tissue-engineering cartilages, modifying chondrocytes, and other tissue engineering technologies for treating traumatic and degenerative joint diseases is estimated to drive the market growth in the upcoming years. Additionally, increasing use of regenerative medicines in hepatocyte transplants for chronic liver disease treatments and liver failure conditions is propelling an exponential growth in the global market.

Moreover, increasing use of poly-hemoglobin blood substitute produced through regenerative medicines to treat conditions of blood contamination or blood shortages is further propelling growth in the utilization of regenerative medicines in the hospitals, blood banks and research institutes.

Tissue engineering is a field majorly focused on development of tissue and organ substitutes by controlling biological, biophysical and/or Biomechanical parameters in the laboratory. Of late, tissue engineering has gained popularity on the back of its utilization to bioengineer implantable devices, reconstitutedecellularized organs, and manufacture organs using3D bio-printing.

Additionally, rising geriatric population across the globe holds immense opportunities for regenerative medicines in the upcoming years. According to World Bank, population aged 65 and above increased from 7.64% in 2010 to 8.926% of the overall population in 2018. Moreover, change in climatic conditions and increase in sedentary lifestyles has led to drastic demographic changes in developed and developing countries, resulting in growing number of disease cases associated with aging. This aspect is attributed to contribute considerably to the regenerative medicines market growth across the globe

Changing environmental conditions with increasing penetration of ultraviolet rays to the earths surface due to global warming consequently impacting the human health by causing oncologic and dermatology based diseases is attributed to create an upsurge in demand for regenerative medicines during the forthcoming years.

Additionally, increasing exposure of the present population to X-rays and gamma rays due to high nuclear energy involving practices is increasing incidences of cancer, subsequently propelling the regenerative medicines market across North America.

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

A sharp reduction in the size of secondary care institutions across Europe in the past decade has resulted in the streamlining of healthcare delivery and stimulated more efficient and integrated model of care that is anticipated to lead to complete conquer of the hospital-centric pattern of care over the forthcoming years. These change in patterns of healthcare are attributed to influence the regenerative medicines market positively across Europe

Increasing prevalence of diabetes retinopathy with rising cases of diabetes mellitus across Asia has resulted in rise in adoption of regenerative medicines for cornea regeneration and other ophthalmic applications driving the market subsequently in the continent over the past. Besides, new application discoveries in the field of regenerative medicines through extensive research and development activities across the countries of India, Japan and China are anticipated to boost the market positively during the forecast period

The Final Report will cover the impact analysis of COVID-19 on this industry (Global and Regional Market).

Request for Complete Report:https://www.kennethresearch.com/sample-request-10166486

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations, and organizations with the aim of helping them to take prominent decisions. Our research library comprises more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both the macro level as well as micro-level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis of various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keeps a track of the international and domestic market for any economic changes impacting the products demand, growth, and opportunities for new and existing players.

New Research Reports Available @Kenneth Research:

Competitive Local Exchange Carriers (CLEC) MarketOnline Grocery MarketOil Gas Automation Control (AC) MarketOil and Gas Cementing Services MarketNeuromodulation Devices Market

Original post:
Global, The US and Europe Regenerative Medicines Market Outlook 2019-2027 Share, Consequence of COVID-19 on Market, Demand, Top Companies, Trend,...

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma – Yahoo Finance

By adminMay 30, 2020Stem Cell Doctors

Call Will Feature Ronald Levy, MD (Stanford University) and Pierluigi Porcu, MD (Thomas Jefferson University)

SAN DIEGO, May 28, 2020 /PRNewswire/ --Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that it will host a key opinion leader (KOL) call discussing the treatment of Epstein-Barr virus (EBV)-associated lymphoma on Friday, June 5th at 12 P.M. Eastern Time.

The call will feature presentations by Key Opinion Leaders Ronald Levy, MD (Stanford University) and Pierluigi Porcu, MD (Thomas Jefferson University), who will discuss the current treatment landscape and unmet medical need in EBV-associated lymphoma. The call will be followed by a question and answer session with Drs. Levy and Porcu. Dial-in and webcast information for the call is shown below.

Dial-in and Webcast Information

Domestic:

1-877-705-6003

International:

1-201-493-6725

Conference ID:

13704262

Webcast:

Click Here For Webcast

On the call, Viracta's management team will also provide an update on the clinical development of the company's lead program, nanatinostat in combination with the antiviral valganciclovir as an oral combination therapy in a Phase 2 clinical trial for the treatment of EBV-associated lymphoma.

About the KOLs

Dr. Ronald Levy is a Professor of Medicine and former Chief of the Division of Oncology at Stanford University School of Medicine. Dr. Levy is widely known as a pioneer in the use of monoclonal antibodies for the treatment of cancer. His research efforts have focused on the treatment of lymphoma and he played a key role in developing Rituximab, a drug that has revolutionized lymphoma treatment world-wide. Among many other honors, Dr. Levy was a recipient of the King Faisal International Prize in Medicine.Dr. Levy's current research concentrates on the development of therapeutic vaccine approaches for the treatment of lymphoma and other cancers.

Dr. Pierluigi Porcu is a Professor of Medical Oncology and Director of the Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation in the Department of Medical Oncology at Thomas Jefferson University, and a member of the Sidney Kimmel Cancer Center (SKCC).Dr. Porcu's Lab at the SKCC is focused on studying the role of the EBV in a subset of T-cell and NK-cell lymphomas, epigenetic mechanisms of T-cell and NK-cell transformation, new targets of therapy in EBV-associated T-cell and NK-cell lymphomas, and predictive biomarkers of response to epigenetic therapy in lymphoma. For the past 10 years, Dr. Porcu has been listed among the U.S. News & World Report's Top Cancer Doctors in America, Newsweek's Top Hematology Doctors, and since moving to Philadelphia he has been on Philadelphia Magazine's Top Doctors list.

About Nanatinostat

Nanatinostat (VRx-3996) is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta.Nanatinostat is selective for specific isoforms of Class 1 HDACs which is key to inducing latent viral genes in EBV-associated malignancies. The nanatinostat and valganciclovir combination is being investigated in EBV-associated lymphomas in an ongoing Phase 2 clinical trial [NCT03397706].

Viracta has received Fast Track designation from the FDA for the nanatinostat and valganciclovir combination in relapsed/refractory lymphomas, as well as Orphan Drug Designation for the treatment of post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T-cell lymphoma.

About EBV-Associated Cancers

Approximately 95% of the world's adult population is infected with Epstein-Barr virus (EBV). Infections are commonly asymptomatic. Following infection, the virus remains latent in a small subset of lymphatic cells for the duration of the patient's life. Under certain circumstances, such cells may undergo malignant transformation and become lymphoma. In addition to lymphomas, EBV is associated with a variety of solid tumors, including nasopharyngeal carcinoma and gastric cancer.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for Epstein-Barr virus positive lymphomas. Viracta is pursuing application of this Kick and Kill platform approach in other EBV associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma and other viral related cancers.

Story continues

See more here:
Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma - Yahoo Finance

As Japan reopens, coronavirus testing slowed by bureaucracy and staff shortages – KDAL News

By adminMay 30, 2020Stem Cell Doctors

Wednesday, May 27, 2020 8:34 p.m. CDT by Thomson Reuters

By Ju-min Park and Kiyoshi Takenaka

TOKYO (Reuters) - At the beginning of April, a young Japanese sumo wrestler known as Shobushi came down with a fever. His coaches tried calling a local public health centre to get him a coronavirus test, but the phone lines were busy.

For four days, he was turned away by clinics in Tokyo overwhelmed during a surge of COVID-19 cases. He was finally admitted to hospital on April 8 when he began coughing up blood, but died of the disease on May 13, the Japan Sumo Association said.

Shobushi's death caused a public outcry over Japan's testing limitations and reliance on overstretched public health centres at a time when most experts say widespread virus checks are crucial to contain the pandemic.

With Japan lifting its state of emergency and reopening its economy this week, its pandemic response has been hailed as an unlikely success. In a global death toll of more than 300,000, Japan has confirmed around 800 deaths from 16,000 cases.

Yet at the same time, Japan ranks the second lowest in its testing among OECD countries.

As of May 20, Japan conducted 3.4 tests per 1,000 people, far below Italy's 52.5 and 39 in the United States, according to Oxford University data. South Korea has carried out tests on 15 people per 1,000 people.

In more than a dozen interviews with Reuters, public health officials, doctors and experts warned Japan's slow scaling up of tests could mask the scale of infections and make its population vulnerable to future outbreaks.

Critics say vested interests and bureaucracy inside Japan's health ministry caused bottlenecks at overworked public health centres, and officials waited too long to allow private labs to run tests.

"It is true that announced figures for infection and deaths are low, but those are based on the tests that were curbed," said Yasuharu Tokuda, the director of the Muribushi Okinawa Center for Teaching Hospitals. "It is clear that there are quite a few (cases) that have fallen through the cracks."

Even the government's top advisor, Shigeru Omi, told parliament "nobody knows" whether the true number of coronavirus cases "could be 10 times, 12 times or 20 times more than reported."

Omi's panel of experts has called on the government to speed up testing, including of people with mild symptoms.

The health ministry said it is ramping up the use of private labs to reduce the workload on public health centres.

"Our stance that tests should be conducted on people in need has been consistent from the beginning. We have had testing capacity increased continuously," Takuma Kato, a senior health ministry official, told Reuters.

"NOT ENOUGH" TESTS

Public health centres are at the forefront of Japan's response to the pandemic. While South Korea bolstered its public health system in the wake of past epidemics, Japan has halved the number of public health centres since the 1990s.

Struggling with overworked staff and flooded with calls, public health centres have asked the government to allow more private clinics to administer polymerase chain reaction (PCR) tests.

Japan says it can run up to 22,000 PCR tests a day, but less than a third - around 6,000 tests - are actually conducted on a daily basis. About 75% of tests have been processed through public health centres and government institutions, according to the health ministry.

In a previously unreported May 6 letter, the association of public health centre directors urged Katsunobu Kato, the minister of health, to overhaul Japan's testing policy.

"Currently, there are not enough PCR tests conducted for the coronavirus," they wrote in the letter seen by Reuters.

Some regional governments have begun running temporary testing stations with the help of local medical associations in April, bypassing public centres.

IDLE LABS, UNUSED MACHINES

While public health centres are overwhelmed, university labs are sitting idle.

Shinya Yamanaka, a Nobel Prize-winning stem cell biologist at Kyoto University, has offered his lab to boost testing capacity.

"If we can make good use of resources at places like university labs, PCR testing can exceed 100,000 (per day), far more than 20,000," Yamanaka said in an internet TV debate with Prime Minister Shinzo Abe on May 6.

The health ministry welcomed his proposal, but said further considerations were needed.

"We are grateful for their offer of help at this time of emergency. We want to work together, carefully matching our needs to their offer," Masami Sakoi, the assistant health minister, told Reuters.

Critics say testing was limited, in part, by health ministry technocrats who wanted to maintain a tight grip on information, rather than cooperate with private institutions.

Kenji Shibuya, who heads the Institute for Population Health at King's College London, said officials wanted to gather high-quality research data using public health centres.

The health ministry denies suggestions that ministry technocrats are intentionally curbing testing, and say their approach has proven successful so far.

Sakoi from the health ministry said it was important to carry out PCR tests that doctors deemed necessary, and pointed out Japan's public insurance system started covering the tests in March as part of the government's effort to make them more accessible.

"When we think about using the test results to form policy measures, the current method needs to be maintained for the time being though concerns that it lacks flexibility for boosting the number of tests is understandable," Sakoi said.

Still, the approach is alarming some experts.

"It's safer to assume that Japan has just been lucky than to believe it has taken the right steps," said Tokuda, the epidemiology expert.

(Reporting by Ju-min Park, Kiyoshi Takenaka, Antoni Slodkowski, Ami Miyazaki, Sakura Murakami; Editing by Mari Saito and Lincoln Feast.)

Follow this link:
As Japan reopens, coronavirus testing slowed by bureaucracy and staff shortages - KDAL News

COTA, Inc. Announces Participation in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and DIA 2020 Virtual Global…

By adminMay 30, 2020Stem Cell Doctors

BOSTON, May 29, 2020 /PRNewswire/ --COTA, Inc., a healthcare technology company that uses real-world data (RWD) to bring clarity to cancer care, is pleased to announce its involvement and participation in two industry leading conferences - the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program taking place May 29-31 and the DIA 2020 Virtual Global Annual Meeting to be held June 14-18. Collectively, the involvement at these two premier events further underscores the importance of RWD's role in clinical research and oncology care delivery.

"As real-world data continues to play an increasing role in clinical research with expanding regulatory applications, COTA is proud to be a leader in the space, and share our expertise and findings at two of the industry's most important meetings," said Mike Doyle, President and CEO of COTA. "Not only are we working to provide clinically relevant insights that might otherwise remain hidden, but we are doing so by collaborating with industry experts, including Friends Of Cancer Research. This work is more important than ever during these unprecedented times, and we look forward to sharing our findings with conference attendees."

ASCO 2020 Areas of Study and Abstracts

The company is proud to announce that five abstracts have been accepted at ASCO's 2020 annual meeting. The key areas of study include the following:

COTA has partnered with leading organizations, life science companies, hospitals, and cancer centers to produce these important findings. Links to the full abstracts and additional author information can be found below:

1. Incorporating molecular markers in standard prognostic models for DLBCL patients using real-world data.

2. Disparities in clinical characteristics and treatment of multiple myeloma in African American patients.

3. Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data.

4.Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration.

5. Assessing real-world clinical response in patients with multiple myeloma (MM): A survey of the literature.

Industry Thought Leaders to Share Expertise at DIA 2020

In addition to its involvement in ASCO20, the Company will also be participating in DIA 2020, leading panel discussions with industry experts and thought leaders.

"As the value of real-world data becomes more accepted and its use more widely adopted, we are looking forward to speaking with industry leaders with invaluable insights on the topic," saidCK Wang, M.D., COTA's Chief Medical Officer. "With expertise spanning from a past Associate Director of the FDA, to an epidemiologist with over 20 years of healthcare research experience, as well as a pharmacoepidemiologist with 25 years of academic and industry experience, these will be fruitful discussions that can help push the industry forward as it expands its use of RWD."

About COTA, Inc.Founded by doctors, engineers and data scientists, COTA is committed to bringing a patient-first approach to cancer care through the use of real-world evidence. The Company organizes fragmented, often hidden data from the real world to provide clarity in cancer care. Combining clinical expertise in cancer with proprietary technology and advanced analytics, COTA helps inform decisions and action in oncology. COTA partners with providers, payers, and life science companies to ensure that everyone touched by cancer has a clear path to the right care. To learn more about COTA and how to make better decisions with the right data, visit cotahealthcare.com.

For more information, please contact:

Jaimee Ryan

Jessika Parry

COTA, Inc.

Next Step Communications

Jaimeeryan@cotahealthcare.com

COTA@nextstepcomms.com

617-733-5509

781-308-3317

View original content to download multimedia:http://www.prnewswire.com/news-releases/cota-inc-announces-participation-in-the-2020-american-society-of-clinical-oncology-asco-virtual-scientific-program-and-dia-2020-virtual-global-annual-meeting-301067654.html

SOURCE Cota

Here is the original post:
COTA, Inc. Announces Participation in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and DIA 2020 Virtual Global...

Scots mum, 28, who lost newborn baby tragically dies from lung inflammation weeks after cancer all clear – The Scottish Sun

By adminMay 30, 2020Stem Cell Doctors

A MUM who lost her newborn baby and battled cancer twice has tragically died.

Danielle Currie, 28, sadly passed away on May 11 - just weeks after being told she could leave Glasgow's Beatson Oncology Centre.

The mum, from Drumchapel, had undergone a successful stem cell transplant in February following a second diagnosis of Hodgkins Lymphoma.

Danielle left the Beatson, where she had been treated after the op, on March 23 - but was rushed to the Queen Elizabeth University Hospital with a high temperature two weeks later.

She tragically passed away on May 11, with her loved ones revealing her death certificate states the cause of death as inflammation of the lungs and pneumonitis

A fundraising page has been set up in her name to raise money for her fiance, Derrick McNaught, 28.

Danielle gave birth to twins Grahame and Sofia McNaught in December 2017, who arrived after just 24 weeks and weighed just one pound, six ounces and one pound, two ounces, respectively.

Heartbreakingly, Grahame died at only 11 days old - but miracle sister Sofia battled against a chronic lung condition to survive.

Home carer Danielle was diagnosed with Hodgkins Lymphona in October 2018, just weeks after her daughter had been allowed to leave hospital.

Cousin Leanne Dawson told the Daily Record: "Danielle and Derrick went through such a hard time after the twins were born. Then came the cancer diagnosis.

"Danielle never said 'why me?' She just got on with it and kept smiling."

"She lost her hair with chemotherapy and often took infections which is horrible, especially for someone of her age.

"She was a new mum and couldn't look after her baby. But she carried on and stayed positive."

Danielle went into remission in March 2019 but the cancer returned a few months later in July.

Leanne, 38, said: "Danielle never said 'why me?' She just got on with it and kept smiling.

"Planning her wedding to Derrick and getting better for Sofia was a good focus for her.

"If anything, she always worried about everyone else, which just summed her up."

After getting the all clear for a second time in March, Danielle headed home the shield with at-risk daughter Sofia.

But in April, she was admitted to hospital and sadly passed away in May.

Leanne, from West Lothian, said: "Her lungs were damaged and had to be drained of liquid, which doctors said could have been a result of the stem cell transplant. It was a horrible time."

Heartbroken Derrick, who cannot work due to his Epilepsy, is now caring for Sofia. But the tot was among the many loved ones who couldn't attend Danielle's funeral this week due to lockdown restrictions.

'OBSESSED'Sturgeon's sassy response to claims she's broken lockdown and had hair done

Pictured

'STAY LOCAL'Scots obey new lockdown rules as beaches stay quiet despite scorching heat

Exclusive

'WISEN UP'Teen killer's Glasgow home targeted by vigilantes after he bragged about crime

Breaking

Virus CrisisAnother 22 Scots die overnight from Covid-19 as death toll hits 2,353

Exclusive

THIRST AIDGlasgow pub proves massive lockdown hit after it reopens to sell takeaway pints

TRAVEL RULESSturgeon puts no legal limit on how far Scots can travel from tomorrow

A GoFundMe page set up to support Derrick and Sofia has well surpassed the original target of 2,000 and has raised more than 5,600.

Over 180 people have donated money to the family during this tragic time.

To donate to the page, click here.

We pay for your stories and videos! Do you have a story or video for The Scottish Sun? Email us at scoop@thesun.co.uk or call 0141 420 5300

Continue reading here:
Scots mum, 28, who lost newborn baby tragically dies from lung inflammation weeks after cancer all clear - The Scottish Sun

"COVID-19: Treatment or vaccines? What seems more likely, and what could be more beneficial?" – Kalkine Media

By adminMay 30, 2020Stem Cell Doctors

According to WHO data, as on 29 May 2020 (at 7:02 PM CEST), there were more than 5.7 million confirmed cases, and over 357k deaths recorded worldwide. COVID-19 has taken lives, shut down economies, and has made people cocooned to their respective homes. However, for the healthcare sector, COVID-19 has presented one of the most significant financial opportunities. What the world currently needs is a potent medicine for treating the virus or an effective vaccine to prevent COVID-19 from affecting people. The struggle lies whether to create a treatment or develop a vaccine. Lets dig dipper on this situation.

COVID-19 and its current treatments

According to the World Health Organization (WHO), COVID-19 acts as a pneumonia-like illness as it creates shortness of breath affecting lungs. However, over time, it has been found that the virus affects the other organs as well, such as kidneys, liver, skin, and brain. At present, the treatments primarily consist of existing antivirals or drugs approved for other indications. Doctors are also using EUA drugs to treat people suffering from SARS-CoV-2 induced disease. A EUA or emergency use authorization from the US Food and Drug Administration (FDA) allows doctors to use the drug for medication without following proper FDA approval process.

Currently, the FDA has assigned emergency use authorization (EUA) to three drugs Chloroquine and Hydroxychloroquine indicated for Malaria, remdesivir indicated for Viral and a sedation drug to be used with FDA.

Sorrento Therapeutics (NASDAQ:SRNE) recently announced that it had developed an antibody drug that had shown positive results in early testing by blocking the COVID-19 strain. According to the company, the drug can be used for treatment as well as to prevent infection.

In Australia, many companies are developing COVID-19 treatments using various platforms

Mesoblast Limited (ASX:MSB) and Cynata (ASX:CYP) are using stem cell therapies and have launched clinical trials to see if the overactive inflammatory response of the body can be reduced.

Cancer biotech Noxopharm (ASX:NOX) has submitted a pre-IND (Investigational New Drug) for Veyonda clinical trial for treating inflammation caused by COVID-19. Antiviral condom lube maker Starpharma (ASX:SPL) claimed its active ingredient acted positively against COVID-19 infection in the lab. However, the efficacy and safety of the drugs still need to be ensured. And hence, there is a delay in proper approved treatments entering the markets.

According to industry experts, COVID-19 is expected to become a seasonal disease every year, making treatments an essential need, and thus, a viable opportunity for pharmaceutical and biotech companies to invest in developing the treatment.

ALSO READ:COVID-19 Treatment: Developments in Australia

While treatment is the need of the hour, vaccines will go a long way

A vaccine protects people to build immunity against an antibody or SARS-CoV-2 in case of COVID-19. A virus will have no effect on vaccinated people. According to WHO, as on 27 May 2020, there are 10 COVID-19 vaccine candidates under clinical assessment and 115 COVID-19 vaccine candidates in pre-clinical stage.

Currently, Moderna Inc (NASDAQ:MRNA) is testing its messenger RNA (mRNA) vaccine in a phase I clinical trial in Seattle, Washington. Moderna is expected to start a phase II study of its vaccine in May 2020 and a phase III clinical trial in July. FDA has agreed to fast-track review upon phase III clinical trial success of the vaccine.

Inovio Pharmaceuticals Inc (NASDAQ:INO) has also quickly developed a potential vaccine for SARS-CoV-2 with phase I clinical trial enrollment completed in late April. The company is expected to start a phase II/III clinical trial in the summer.

The University of Queensland in Australia has a research team which is developing a vaccine by growing viral proteins in cell cultures. The group began pre-clinical testing stages in early April. Pharmaceutical companies, Johnson & Johnson and Sanofi are also developing vaccines of their own.

However, according to the director of NIH, Dr Anthony Fauci, a vaccine meant for widespread use will take almost 12 to 18 months to enter the market.

Bottomline

Medicines and vaccines reside side by side. COVID-19 has presented the healthcare sector with an opportunity to serve the people worldwide and rake in big money by creating the right medicine for the treatment of the coronavirus disease, or by developing an effective vaccine to prevent it from affecting people. As per UNICEF Australia, vaccines do assist in building up public health and bring down death rates stemming from various diseases. However, vaccines are not 100% effective, and the vaccination rate per country also varies, creating an earnest need for prescribed medicines to beat the novel coronavirus.

Do Read: How Healthcare and Research Companies are coming up with Ground-Breaking Technologies to Deal with COVID-19

The rest is here:
"COVID-19: Treatment or vaccines? What seems more likely, and what could be more beneficial?" - Kalkine Media

New human-mouse chimera is the most human yet – Livescience.com

By adminMay 30, 2020Stell Cell Research

A newly-created mouse-human embryo contains up to 4% human cells the most human cells yet of any chimera, or an organism made of two different sets of DNA.

Surprisingly, those human cells could learn from the mouse cells and develop faster at the pace of a mouse embryo rather than a more slowly developing human embryo. That finding was "very serendipitous We did not really foresee that," said senior author Jian Feng, a professor in the department of physiology and biophysics at the State University of New York at Buffalo.

Successfully growing human cells in mouse embryos might one day help scientists understand the growth and aging process of our bodies and how diseases such as COVID-19 damage cells and could eventually even serve as a scaffold to grow organs for transplantation, Feng said.

Related: The 9 most interesting transplants

Feng and his team tackled a long-standing issue in creating such chimeras: that in order for human embryonic stem cells and mouse embryonic stem cells to chat and mingle, they needed to be in the same state of development. Embryonic stem cells are pluripotent, meaning they can develop into any type of cell in the body.

But "the human embryonic stem cell looks and behaves very differently from the mouse embryonic stem cell," so past attempts to get them to comingle have all failed, Feng told Live Science. At first, researchers thought the failures were due to some kind of species barrier; but after many years of study, they realized that it wasn't a species issue, but rather a maturity one.

The human stem cells were in a later stage of development called a "primed" state, which normally occurs only after the human embryo has already been implanted in the uterine wall. In contrast, the mouse stem cells were in a more "naive" state, which normally occurs when the mouse embryo is still floating around in the fallopian tubes. In the past, researchers weren't able to convert human cells back to this naive state, Feng said.

In their experiments, Feng and his team were inspired by a process called "embryonic diapause" that occurs in hundreds of mammals from bears to mice: When there's some sort of hardship such as a famine or shortage of water, some animals' embryos can remain in the naive state inside a mother's fallopian tubes for months and sometimes over a year for the environment to become more suitable, Feng said.

It's not clear what triggers the embryos to pause in this state, but a protein called mTOR seems to be a sensor that detects when conditions are bad, he said. Feng and his team figured out that they could target this protein inside human stem cells to make the cells think that they were experiencing famine, and needed to jump to a more naive state where they could conserve energy, Feng said.

The protein mTOR normally promotes the production of proteins and other molecules to support cell growth and proliferation, so by inhibiting it, Feng and his team "shocked" the human cells into changing their metabolism and gene expression. "So it behaves pretty much like the mouse cell," Feng said. What resulted was a naive set of human stem cells that could be cultured together with mouse stem cells and "intermingle very nicely," Feng said. The researchers then injected 10 to 12 of these naive human stem cells into mouse embryos.

In most of the mouse embryos, the naive human stem cells successfully developed into mature human cells in all three germ layers: the ectoderm, or the primary cell layers that develop when the embryo is growing and which later develop to form hair, nails, the epidermis and nerve tissue; the mesoderm, or the cells that make up the organs; and the endoderm, or the inner lining of organs. But no human cells spilled over into germline tissue, which develops into egg and sperm cells.

These germ layers then developed into more differentiated cells, and when the researchers stopped their experiment on the 17th day, 14 embryos were between 0.1% and 4% human (some had less human cells and some had more), with human cells found through the embryo, including in the liver, heart, retina and red blood cells.

Related: First pig-monkey chimeras were just created in China

But what was really "surprising" was the speed at which the human cells developed, Feng said. For example, the embryos were able to generate human red blood cells in 17 days, compared to the roughly 56 days red blood cells take to develop in a growing human embryo. Similarly, human eye cells don't develop until much later on in the embryo, whereas within 17 days, human eye cells including photo receptors formed in the chimera. Basically, the human cells "assumed the clock of the mouse embryo," Feng said. Previously, scientists thought this accelerated development was impossible because the tempo of human cell development was always thought to be "kind of immutable," he added.

This paper identifies a "novel way" of turning primed human pluripotent stem cells into a naive state, said Ronald Parchem, an assistant professor in the Stem Cells and Regenerative Medicine Center at Baylor College of Medicine in Texas, who was not a part of the study. But "the level of chimerism is low in this study," compared to another study that developed chimeras with up to 20% human cells per embryo, he said. That study, however, was published to the preprint database Biorxiv on May 24,and hasn't yet been peer-reviewed. "Together, these studies provide insight into capturing pluripotent states in vitro and highlight the barriers preventing successful cross-species chimerism," Parchem said. "Identifying ways to overcome these barriers has the potential to improve regenerative medicine."

These findings might "stimulate research" in the fundamental understanding of human development, especially how time is measured by biological systems, Feng said. Such chimeras could help scientists understand human diseases. For example, researchers might one day be able to regenerate human blood in a mouse model and study diseases such as malaria. Or if you can create human lung cells, or epithelial cells that line the respiratory tract, that mouse can become a "model system" for studying diseases like COVID-19, Feng said. In other words, mice with human cells can be infected with COVID-19 to understand how the virus attacks the body.

The most cited potential application of such chimeras is organ growth. But this likely won't happen in mice but much larger animals such as pigs, he said. Of course, these applications raise ethical issues, he added. One such ethical consideration is that chimeras blur the lines between species and that makes it difficult to determine the morality or the consciousness that those animals possess. For example, chimeras used in animal testing could be given too many human characteristics and have a similar moral status or consciousness to us, according to a previous Live Science report.

Feng said that much discussion needs to take place before such applications can be considered.

"This field requires much more exploration before this becomes a reality," said Carol Ware, the associate director at the University of Washington's Institute for Stem Cell and Regenerative Medicine, who was also not a part of the study. "A couple of the primary hurdles at this point are determining the host species for these human cells," and public acceptance in the work, she added.

"At this point, it would seem that the speed with which this clinical opportunity will become a reality will not be hindered by the ability to grow human organs," she added. "I would have liked to see," what happens when mTOR is taken away inside the lab dish and these naive human cells are allowed to advance again, particularly to see if some key cellular processes resume again, she added.

The findings were published in the journal Science Advances on May 13.

Originally published on Live Science.

Read the original here:
New human-mouse chimera is the most human yet - Livescience.com

Animal Stem Cell Therapy Market Research Report: Probable Key Development To Be Observed Market States And Outlook Across By 2026| – Jewish Life News

By adminMay 30, 2020Stell Cell Research

The market research report published by QYResearch is a brilliant, in-depth, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Animal Stem Cell Therapy market. It informs readers about key trends and opportunities in the global Animal Stem Cell Therapy market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Animal Stem Cell Therapy market.

Key companies operating in the global Animal Stem Cell Therapy market include , Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1499506/global-animal-stem-cell-therapy-industry

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Animal Stem Cell Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Animal Stem Cell Therapy Market Segment By Type:

, Dogs, Horses, Other

Global Animal Stem Cell Therapy Market Segment By Application:

, Veterinary Hospitals, Research Organizations

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Animal Stem Cell Therapy market.

Key questions answered in the report:

For Discount, COVID-19 Impact Analysis, Customization in the Report: https://www.qyresearch.com/customize-request/form/1499506/global-animal-stem-cell-therapy-industry

TOC

Table of Contents 1 Report Overview1.1 Research Scope1.2 Top Animal Stem Cell Therapy Manufacturers Covered: Ranking by Revenue1.3 Market Segment by Type1.3.1 Global Animal Stem Cell Therapy Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)1.3.2 Dogs1.3.3 Horses1.3.4 Others1.4 Market Segment by Application1.4.1 Global Animal Stem Cell Therapy Consumption by Application: 2015 VS 2020 VS 20261.4.2 Veterinary Hospitals1.4.3 Research Organizations1.5 Study Objectives1.6 Years Considered 2 Global Market Perspective2.1 Global Animal Stem Cell Therapy Revenue (2015-2026)2.1.1 Global Animal Stem Cell Therapy Revenue (2015-2026)2.1.2 Global Animal Stem Cell Therapy Sales (2015-2026)2.2 Animal Stem Cell Therapy Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 20262.2.1 Global Animal Stem Cell Therapy Sales by Regions (2015-2020)2.2.2 Global Animal Stem Cell Therapy Revenue by Regions (2015-2020)2.3 Global Top Animal Stem Cell Therapy Regions (Countries) Ranking by Market Size2.4 Animal Stem Cell Therapy Industry Trends2.4.1 Animal Stem Cell Therapy Market Top Trends2.4.2 Market Drivers2.4.3 Animal Stem Cell Therapy Market Challenges 2.4.4 Porters Five Forces Analysis2.4.5 Primary Interviews with Key Animal Stem Cell Therapy Players: Views for Future 3 Competitive Landscape by Manufacturers3.1 Global Top Animal Stem Cell Therapy Manufacturers by Sales (2015-2020)3.1.1 Global Animal Stem Cell Therapy Sales by Manufacturers (2015-2020)3.1.2 Global Animal Stem Cell Therapy Sales Market Share by Manufacturers (2015-2020)3.1.3 Global 5 and 10 Largest Manufacturers by Animal Stem Cell Therapy Sales in 20193.2 Global Top Manufacturers Animal Stem Cell Therapy by Revenue3.2.1 Global Animal Stem Cell Therapy Revenue by Manufacturers (2015-2020)3.2.2 Global Animal Stem Cell Therapy Revenue Share by Manufacturers (2015-2020)3.2.3 Global Animal Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Animal Stem Cell Therapy as of 2019)3.4 Global Animal Stem Cell Therapy Average Selling Price (ASP) by Manufacturers3.5 Key Manufacturers Animal Stem Cell Therapy Plants/Factories Distribution and Area Served3.6 Date of Key Manufacturers Enter into Animal Stem Cell Therapy Market3.7 Key Manufacturers Animal Stem Cell Therapy Product Offered 3.8 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type4.1 Global Animal Stem Cell Therapy Historic Market Review by Type (2015-2020)4.1.2 Global Animal Stem Cell Therapy Sales Market Share by Type (2015-2020)4.1.3 Global Animal Stem Cell Therapy Revenue Market Share by Type (2015-2020)4.1.4 Animal Stem Cell Therapy Price by Type (2015-2020)4.1 Global Animal Stem Cell Therapy Market Estimates and Forecasts by Type (2021-2026)4.2.2 Global Animal Stem Cell Therapy Sales Forecast by Type (2021-2026)4.2.3 Global Animal Stem Cell Therapy Revenue Forecast by Type (2021-2026)4.2.4 Animal Stem Cell Therapy Price Forecast by Type (2021-2026) 5 Global Animal Stem Cell Therapy Market Size by Application5.1 Global Animal Stem Cell Therapy Historic Market Review by Application (2015-2020)5.1.2 Global Animal Stem Cell Therapy Sales Market Share by Application (2015-2020)5.1.3 Global Animal Stem Cell Therapy Revenue Market Share by Application (2015-2020)5.1.4 Animal Stem Cell Therapy Price by Application (2015-2020)5.2 Global Animal Stem Cell Therapy Market Estimates and Forecasts by Application (2021-2026)5.2.2 Global Animal Stem Cell Therapy Sales Forecast by Application (2021-2026)5.2.3 Global Animal Stem Cell Therapy Revenue Forecast by Application (2021-2026)5.2.4 Animal Stem Cell Therapy Price Forecast by Application (2021-2026) 6 North America6.1 North America Animal Stem Cell Therapy Breakdown Data by Company6.2 North America Animal Stem Cell Therapy Breakdown Data by Type6.3 North America Animal Stem Cell Therapy Breakdown Data by Application6.4 North America Animal Stem Cell Therapy Breakdown Data by Countries6.4.1 North America Animal Stem Cell Therapy Sales by Countries6.4.2 North America Animal Stem Cell Therapy Revenue by Countries6.4.3 U.S.6.4.4 Canada 7 Europe7.1 Europe Animal Stem Cell Therapy Breakdown Data by Company7.2 Europe Animal Stem Cell Therapy Breakdown Data by Type7.3 Europe Animal Stem Cell Therapy Breakdown Data by Application7.4 Europe Animal Stem Cell Therapy Breakdown Data by Countries7.4.1 Europe Animal Stem Cell Therapy Sales by Countries7.4.2 Europe Animal Stem Cell Therapy Revenue by Countries7.4.3 Germany7.4.4 France7.4.5 U.K.7.4.6 Italy7.4.7 Russia 8 Asia Pacific8.1 Asia Pacific Animal Stem Cell Therapy Breakdown Data by Company8.2 Asia Pacific Animal Stem Cell Therapy Breakdown Data by Type8.3 Asia Pacific Animal Stem Cell Therapy Breakdown Data by Application8.4 Asia Pacific Animal Stem Cell Therapy Breakdown Data by Regions8.4.1 Asia Pacific Animal Stem Cell Therapy Sales by Regions8.4.2 Asia Pacific Animal Stem Cell Therapy Revenue by Regions8.4.3 China8.4.4 Japan8.4.5 South Korea8.4.6 India8.4.7 Australia8.4.8 Taiwan8.4.9 Indonesia8.4.10 Thailand8.4.11 Malaysia8.4.12 Philippines8.4.13 Vietnam 9 Latin America9.1 Latin America Animal Stem Cell Therapy Breakdown Data by Company9.2 Latin America Animal Stem Cell Therapy Breakdown Data by Type9.3 Latin America Animal Stem Cell Therapy Breakdown Data by Application9.4 Latin America Animal Stem Cell Therapy Breakdown Data by Countries9.4.1 Latin America Animal Stem Cell Therapy Sales by Countries9.4.2 Latin America Animal Stem Cell Therapy Revenue by Countries9.4.3 Mexico9.4.4 Brazil9.4.5 Argentina 10 Middle East and Africa10.1 Middle East and Africa Animal Stem Cell Therapy Breakdown Data by Type10.2 Middle East and Africa Animal Stem Cell Therapy Breakdown Data by Application10.3 Middle East and Africa Animal Stem Cell Therapy Breakdown Data by Countries10.3.1 Middle East and Africa Animal Stem Cell Therapy Sales by Countries10.3.2 Middle East and Africa Animal Stem Cell Therapy Revenue by Countries10.3.3 Turkey10.3.4 Saudi Arabia10.3.5 U.A.E 11 Company Profiles11.1 Medivet Biologics LLC11.1.1 Medivet Biologics LLC Corporation Information11.1.2 Medivet Biologics LLC Business Overview and Total Revenue (2019 VS 2018)11.1.3 Medivet Biologics LLC Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.1.4 Medivet Biologics LLC Animal Stem Cell Therapy Products and Services11.1.5 Medivet Biologics LLC SWOT Analysis11.1.6 Medivet Biologics LLC Recent Developments11.2 VETSTEM BIOPHARMA11.2.1 VETSTEM BIOPHARMA Corporation Information11.2.2 VETSTEM BIOPHARMA Business Overview and Total Revenue (2019 VS 2018)11.2.3 VETSTEM BIOPHARMA Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.2.4 VETSTEM BIOPHARMA Animal Stem Cell Therapy Products and Services11.2.5 VETSTEM BIOPHARMA SWOT Analysis11.2.6 VETSTEM BIOPHARMA Recent Developments11.3 J-ARM11.3.1 J-ARM Corporation Information11.3.2 J-ARM Business Overview and Total Revenue (2019 VS 2018)11.3.3 J-ARM Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.3.4 J-ARM Animal Stem Cell Therapy Products and Services11.3.5 J-ARM SWOT Analysis11.3.6 J-ARM Recent Developments11.4 U.S. Stem Cell, Inc11.4.1 U.S. Stem Cell, Inc Corporation Information11.4.2 U.S. Stem Cell, Inc Business Overview and Total Revenue (2019 VS 2018)11.4.3 U.S. Stem Cell, Inc Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.4.4 U.S. Stem Cell, Inc Animal Stem Cell Therapy Products and Services11.4.5 U.S. Stem Cell, Inc SWOT Analysis11.4.6 U.S. Stem Cell, Inc Recent Developments11.5 VetCell Therapeutics11.5.1 VetCell Therapeutics Corporation Information11.5.2 VetCell Therapeutics Business Overview and Total Revenue (2019 VS 2018)11.5.3 VetCell Therapeutics Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.5.4 VetCell Therapeutics Animal Stem Cell Therapy Products and Services11.5.5 VetCell Therapeutics SWOT Analysis11.5.6 VetCell Therapeutics Recent Developments11.6 Celavet Inc.11.6.1 Celavet Inc. Corporation Information11.6.2 Celavet Inc. Business Overview and Total Revenue (2019 VS 2018)11.6.3 Celavet Inc. Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.6.4 Celavet Inc. Animal Stem Cell Therapy Products and Services11.6.5 Celavet Inc. SWOT Analysis11.6.6 Celavet Inc. Recent Developments11.7 Magellan Stem Cells11.7.1 Magellan Stem Cells Corporation Information11.7.2 Magellan Stem Cells Business Overview and Total Revenue (2019 VS 2018)11.7.3 Magellan Stem Cells Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.7.4 Magellan Stem Cells Animal Stem Cell Therapy Products and Services11.7.5 Magellan Stem Cells SWOT Analysis11.7.6 Magellan Stem Cells Recent Developments11.8 Kintaro Cells Power11.8.1 Kintaro Cells Power Corporation Information11.8.2 Kintaro Cells Power Business Overview and Total Revenue (2019 VS 2018)11.8.3 Kintaro Cells Power Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.8.4 Kintaro Cells Power Animal Stem Cell Therapy Products and Services11.8.5 Kintaro Cells Power SWOT Analysis11.8.6 Kintaro Cells Power Recent Developments11.9 Animal Stem Care11.9.1 Animal Stem Care Corporation Information11.9.2 Animal Stem Care Business Overview and Total Revenue (2019 VS 2018)11.9.3 Animal Stem Care Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.9.4 Animal Stem Care Animal Stem Cell Therapy Products and Services11.9.5 Animal Stem Care SWOT Analysis11.9.6 Animal Stem Care Recent Developments11.10 Animal Cell Therapies11.10.1 Animal Cell Therapies Corporation Information11.10.2 Animal Cell Therapies Business Overview and Total Revenue (2019 VS 2018)11.10.3 Animal Cell Therapies Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.10.4 Animal Cell Therapies Animal Stem Cell Therapy Products and Services11.10.5 Animal Cell Therapies SWOT Analysis11.10.6 Animal Cell Therapies Recent Developments11.11 Cell Therapy Sciences11.11.1 Cell Therapy Sciences Corporation Information11.11.2 Cell Therapy Sciences Business Overview and Total Revenue (2019 VS 2018)11.11.3 Cell Therapy Sciences Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.11.4 Cell Therapy Sciences Animal Stem Cell Therapy Products and Services11.11.5 Cell Therapy Sciences SWOT Analysis11.11.6 Cell Therapy Sciences Recent Developments11.12 Animacel11.12.1 Animacel Corporation Information11.12.2 Animacel Business Overview and Total Revenue (2019 VS 2018)11.12.3 Animacel Animal Stem Cell Therapy Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.12.4 Animacel Animal Stem Cell Therapy Products and Services11.12.5 Animacel SWOT Analysis11.12.6 Animacel Recent Developments 12 Supply Chain and Sales Channels Analysis 12.1 Supply Chain Analysis 12.2 Sales Channels Analysis12.2.1 Animal Stem Cell Therapy Sales Channels12.2.2 Animal Stem Cell Therapy Distributors12.3 Animal Stem Cell Therapy Customers 13 Estimates and Projections by Regions (2021-2026)13.1 Global Animal Stem Cell Therapy Sales Forecast (2021-2026)13.1.1 Global Animal Stem Cell Therapy Sales Forecast by Regions (2021-2026)13.1.2 Global Animal Stem Cell Therapy Revenue Forecast by Regions (2021-2026) 13.2 North America Market Size Forecast (2021-2026)13.2.1 North America Animal Stem Cell Therapy Sales Forecast (2021-2026)13.2.2 North America Animal Stem Cell Therapy Revenue Forecast (2021-2026)13.2.3 North America Animal Stem Cell Therapy Size Forecast by County (2021-2026) 13.3 Europe Market Size Forecast (2021-2026)13.3.1 Europe Animal Stem Cell Therapy Sales Forecast (2021-2026)13.3.2 Europe Animal Stem Cell Therapy Revenue Forecast (2021-2026)13.3.3 Europe Animal Stem Cell Therapy Size Forecast by County (2021-2026) 13.4 Asia Pacific Market Size Forecast (2021-2026)13.4.1 Asia Pacific Animal Stem Cell Therapy Sales Forecast (2021-2026)13.4.2 Asia Pacific Animal Stem Cell Therapy Revenue Forecast (2021-2026)13.4.3 Asia Pacific Animal Stem Cell Therapy Size Forecast by Region (2021-2026) 13.5 Latin America Market Size Forecast (2021-2026)13.5.1 Latin America Animal Stem Cell Therapy Sales Forecast (2021-2026)13.5.2 Latin America Animal Stem Cell Therapy Revenue Forecast (2021-2026)13.5.3 Latin America Animal Stem Cell Therapy Size Forecast by County (2021-2026) 13.6 Middle East and Africa Market Forecast13.6.1 Middle East and Africa Animal Stem Cell Therapy Sales Forecast (2021-2026)13.6.2 Middle East and Africa Animal Stem Cell Therapy Revenue Forecast (2021-2026)13.6.3 Middle East and Africa Animal Stem Cell Therapy Size Forecast by County (2021-2026) 14 Research Findings and Conclusion 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Author Details15.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.